"mRNA Therapy Trial Shows Promise in Treating Rare Inherited Disease"
A new mRNA therapy, mRNA-3927, shows promise in treating propionic acidemia, an ultrarare inherited metabolic disorder that affects around 1 in 100,000 people in the U.S. The therapy aims to replenish stocks of working enzymes in the body by using messenger RNA to produce fully functioning enzymes that are otherwise defective in patients with the disease. Initial findings from a pioneering clinical trial suggest a 70% drop in the rate of metabolic decompensation events in patients with propionic acidemia, although the trial has several limitations and is ongoing.
